The Phosphodiesterase Inhibitor Pentoxifylline as an Adjuvant in Treatment of Negative Symptoms in Chronic Schizophrenia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study to evaluate the efficacy and safety of pentoxifylline, the novel
phosphodiesterase inhibitor, as an adjunctive to risperidone in alleviating the negative
symptoms of schizophrenia.